Cryptococcosis

Not to be confused with Cryptosporidiosis.

Cryptococcosis
Other names	Busse-Buschke disease, cryptococcic meningitis, cryptococcosis lung, cryptococcosis skin, European Blastomycosis, torular meningitis, torulosis [1]
Micrograph of cryptococcosis showing the characteristically thick capsule of cryptococcus. Field stain.
Pronunciation	/ˌkrɪptəkəˈkoʊsɪs,-toʊ-,-kɒ-/ [2] [3]
Specialty	Infectious disease [4]
Symptoms	Lung: Cough, difficulty breathing, chest pain and fever. [5] Brain: Headache, fever, neck pain, nausea, vomiting, light sensitivity, confusion, change in behaviour. [5] Skin: Nodules with dead tissue. [6]
Causes	Cryptococcus neoformans , [7] Cryptococcus gattii [8]
Risk factors	HIV/AIDS, [9] Aviculture
Diagnostic method	Biopsy, culture [9]
Treatment	Antifungal medication
Medication	Fluconazole [10] Amphotericin B [9] Flucytosine [11]

Cryptococcosis is a potentially fatal fungal infection of mainly the lungs, presenting as a pneumonia, and in the brain, where it appears as a meningitis. ^{[4] [9]} Coughing, difficulty breathing, chest pain and fever are seen when the lungs are infected. ^[5] When the brain is infected, symptoms include headache, fever, neck pain, nausea and vomiting, light sensitivity and confusion or changes in behavior. ^[5] It can also affect other parts of the body including skin, where it may appear as several fluid-filled nodules with dead tissue. ^[6]

It is caused by the fungi Cryptococcus neoformans or less commonly Cryptococcus gattii , and is acquired by breathing in the spores from the air. ^[4] These fungi are found around the world in soil, decaying wood, pigeon droppings, and in the hollows of some species of trees. ^{[9] [12]} Whereas C. neoformans generally infects people with HIV/AIDS and those on immunosuppressant drugs and does not usually affect fit and healthy people, C. gattii (found in some parts of Canada and the US) does. ^{[9] [12]} Once breathed in, the dried yeast cells colonize the lungs, where they are either cleared by immune cells, lie dormant, or cause infection and spread. ^[13]

Diagnosis is by isolating Cryptococcus from a sample of affected tissue or direct observation of the fungus by using staining of body fluids. ^[9] It can be cultured from a cerebrospinal fluid, sputum, and skin biopsy. ^[9] Treatment is with fluconazole or amphotericin B. ^{[9] [10]}

Data from 2009 estimated that of the almost one million cases of cryptococcal meningitis that occurred worldwide annually, 700,000 occurred in sub-Saharan Africa and 600,000 per year died. ^[14] Cryptococcosis was rare before the 1970s which saw an increase in at-risk groups such as people with organ transplant or on immunosuppressant medications. ^[9] The number of cases escalated in the mid-1980s with over 80% occurring in people with HIV/AIDS. ^[9] Pigeon breeders (or otherwise people who spend significant time with pigeons) are known to have a high incidence of cryptococcal infections including primary cutaneous cryptococcus due to the fungi's association with pigeon droppings. ^{[15] [ better source needed ]}

Classification

Cryptococcus is generally classified according to how it is acquired and the site of infection. ^[16] It typically begins in the lungs before spreading to other parts of the body, particularly the brain and nervous system. ^[1] Skin involvement is less common. ^[1]

Signs and symptoms

Cough, shortness of breath, chest pain and fever are seen when the lungs are infected, appearing like a pneumonia. ^[5] There may also be feeling of tiredness. ^[4] When the brain is infected, symptoms include headache, fever, neck pain, nausea and vomiting, light sensitivity, confusion or changes in behaviour. ^[5] It can also affect other parts of the body including skin, eyes, bones and prostate. ^[9] In the skin, it may appear as several fluid-filled nodules with dead tissue. ^[6] Depending on the site of infection, other features may include loss of vision, blurred vision, inability to move an eye and memory loss. ^[9]

Symptom onset is often sudden when lungs are infected and gradual over several weeks when the central nervous system is affected. ^[9]

Signs and symptoms of cryptococcal infection may be delayed in those with HIV or AIDS. A positive cryptococcal antigen test may precede symptoms by 3 weeks in those with HIV/AIDS. Others may have re-activation of latent cryptococcal disease years later. In those with HIV, approximately 50% of people have a fever, but fever is rare in previously healthy and immunocompetent people with cryptococcosis. ^[17]

Cause

Cryptococcosis is a common opportunistic infection for AIDS, and is particularly common among people living with AIDS in Africa. Other conditions that pose an increased risk include certain malignancies (such as lymphoma), liver cirrhosis, organ transplants, and long-term corticosteroid therapy. ^[18]

Distribution is worldwide in soil. ^[19] The prevalence of cryptococcosis has been increasing over the past 50 years for many reasons, including the increase in incidence of AIDS and the expanded use of immunosuppressive drugs. ^[20]

In humans, C. neoformans chiefly infects the skin, lungs, and central nervous system (causing meningitis). ^[20] Less commonly it may affect other organs such as the eye or prostate. ^[20]

Primary cutaneous cryptococcosis

Primary cutaneous cryptococcosis (PCC) is a distinct clinical diagnosis separate from the secondary cutaneous cryptococcosis that is spread from systematic infection. Males are more likely to develop the infection and a 2020 study showed that the sex bias may be due to a growth hormone, produced by C. neoformans called gibberellic acid (GA) that is upregulated by testosterone. ^[21] The upper limbs account for a majority of infections. Isolates found in PCC include Cryptococcus neoformans (most common), Cryptococcus gattii , and Cryptococcus laurentii . Prognosis for PCC is generally good outside of disseminated infection. ^[22]

Morphologic description of the lesions show umbilicated papules, nodules, and violaceous plaques that can mimic other cutaneous diseases like molluscum contagiosum and Kaposi's sarcoma. These lesions may be present months before other signs of system infection in patients with AIDS. ^[23]

Pulmonary cryptococcosis

Cryptococcus (both C. neoformans and C. gattii) plays a common role in pulmonary invasive mycosis seen in adults with HIV and other immunocompromised conditions. ^[18] It also affects healthy adults at a much lower frequency and severity as healthy hosts may have no or mild symptoms. ^[24] Immune-competent hosts may not seek or require treatment, but careful observation may be important. ^[25] Cryptococcal pneumonia has a potential to disseminate to the central nervous system (CNS) especially in immunocompromised individuals. ^[26]

Pulmonary cryptococcosis has a worldwide distribution and is commonly underdiagnosed due to limitations in diagnostic capabilities. Since pulmonary nodules are its most common radiological feature, it can clinically and radiologically mimic lung cancer, TB, and other pulmonary mycoses. The sensitivity of cultures and the Cryptococcal (CrAg) antigen with lateral flow device on serum are rarely positive in the absence of disseminated disease. ^[18] Moreover, pulmonary cryptococcosis worsen the prognosis of cryptococcal meningitis. ^[18]

Cryptococcal meningitis

Disseminated cryptococcal meningitis

See also: Chronic meningitis

Cryptococcal meningitis (infection of the meninges, the tissue covering the brain) is believed to result from dissemination of the fungus from either an observed or undetected pulmonary infection. Often there is also silent dissemination throughout the brain when meningitis is present. People with defects in their cell-mediated immunity, for example, people with AIDS, are especially susceptible to disseminated cryptococcosis. Cryptococcosis is often fatal, even if treated. It is estimated that the three-month case-fatality rate is 9% in high-income regions, 55% in low/middle-income regions, and 70% in sub-Saharan Africa. As of 2009 there were globally approximately 958,000 annual cases and 625,000 deaths within three months after infection. ^[27]

Although C. neoformans infection most commonly occurs as an opportunistic infection in immunocompromised people (such as those living with AIDS), C. gattii often infects immunocompetent people as well. ^[28]

Cryptococcus species (both C. neoformans and C. gattii ) are responsible for 68% of meningitis cases in those with HIV. ^[17] Cryptococcus is considered an "emerging" disease in healthy adults. ^[29] Though the rate of infection is clearly higher with immunocompromised individuals, some studies suggest a higher mortality rate in patients with non-HIV cryptococcal meningitis secondary to the role of T-cell mediated reaction and injury. ^[30] CD4+ T cells have proven roles in the defense against Cryptococcus, but it can also contribute to clinical deterioration due its inflammatory response. ^[31]

Diagnosis

Symptom onset is often subacute, progressively worsened over several weeks, and delays in diagnosis are associated with increased mortality. ^{[20] [17]}

Cerebrospinal fluid (CSF) or blood antigen testing by lateral flow assay for cryptococcal antigens has a sensitivity and specificity greater than 99% for cryptococcosis. ^[17] A CSF fungal culture can tell if there is microbiological failure (failure of the fungal infections to treat the infection). CSF fungal culture has a 90% sensitivity and 100% specificity for the diagnosis of cryptococcal meningitis. CSF cell analysis is characterized by increased lymphocytes, reduced protein and reduced glucose. ^[17] For any person who has cryptococcosis at a site outside of the central nervous system (e.g., pulmonary cryptococcosis), a lumbar puncture is indicated to evaluate the cerebrospinal fluid (CSF) for evidence of cryptococcal meningitis, even if they do not have signs or symptoms of CNS disease. Detection of cryptococcal antigen (capsular material) by culture of CSF, sputum and urine provides definitive diagnosis. ^[32] Blood cultures may be positive in heavy infections. India ink of the CSF is a traditional microscopic method of diagnosis, ^[33] although the sensitivity is poor in early infection, and may miss 15–20% of patients with culture-positive cryptococcal meningitis. ^[34] Rapid diagnostic methods to detect cryptococcal antigen include latex agglutination testing, lateral flow immunochromatographic assay (LFA), or enzyme immunoassay (EIA). Polymerase chain reaction (PCR) has been used on tissue specimens, with PCR having a sensitivity of 82% and a specificity of 98% for cryptococcal infection. ^[17]

• 
• 
• 
• 
• 
• 

Prevention

Cryptococcosis is a very subacute infection with a prolonged subclinical phase lasting weeks to months in persons with HIV/AIDS before the onset of symptomatic meningitis. In Sub-Saharan Africa, the prevalence rates of detectable cryptococcal antigen in peripheral blood is often 4–12% in persons with CD4 counts lower than 100 cells/mcL. ^{[35] [36]} Cryptococcal antigen screen and preemptive treatment with fluconazole is cost saving to the healthcare system by avoiding cryptococcal meningitis. ^[37] The World Health Organization recommends cryptococcal antigen screening in HIV-infected persons entering care with CD4<100 cells/μL. ^[38] This undetected subclinical cryptococcal (if not preemptively treated with anti-fungal therapy) will often go on to develop cryptococcal meningitis, despite receiving HIV therapy. ^{[36] [39]} Cryptococcosis accounts for 20–25% of the mortality after initiating HIV therapy in Africa. What is effective preemptive treatment is unknown, with the current recommendations on dose and duration based on expert opinion. Screening in the United States is controversial, with official guidelines not recommending screening, despite cost-effectiveness and a 3% U.S. cryptococcal antigen prevalence in CD4<100 cells/μL. ^{[40] [41]}

Antifungal prophylaxis such as fluconazole and itraconazole reduces the risk of contracting cryptococcosis in those with low CD4 cell count and high risk of developing such disease in a setting of cryptococcal antigen screening tests are not available. ^[42]

Treatment

Treatment options in persons without HIV-infection have not been well studied. Intravenous Amphotericin B combined with flucytosine by mouth is recommended for initial treatment (induction therapy). ^[43]

People living with AIDS often have a greater burden of disease and higher mortality (30–70% at 10-weeks), recommended therapy is with amphotericin B and flucytosine. Adding flucytosine to amphotericin B is associated with earlier fungal clearance and increased survival, however it is not readily available in many lower income regions. ^[17] Where flucytosine is not available, fluconazole should be used with amphotericin. ^[38] Amphotericin-based induction therapy has much greater microbiologic activity than fluconazole monotherapy with 30% better survival at 10 weeks. ^{[32] [44]} Based on a systematic review, the most cost-effective induction treatment in resource-limited settings appears to be one week of amphotericin B coupled with high-dose fluconazole. ^[44] After initial induction treatment as above, typical consolidation therapy is with oral fluconazole for at least 8 weeks used with secondary prophylaxis with fluconazole thereafter. ^[38]

The decision on when to start treatment for HIV appears to be very different than other opportunistic infections. A large multi-site trial supports deferring ART for 4–6 weeks was overall preferable with 15% better 1-year survival than earlier ART initiation at 1–2 weeks after diagnosis. ^[45] A 2018 Cochrane review also supports the delayed starting of treatment until cryptococcosis starts improving with antifungal treatment. ^[46]

Increased intracranial pressure is seen in about 50% of those with HIV-associated cryptococcal meningitis and is usually associated with a high fungal burden. Regular (often daily) lumbar punctures to lower the intracranial pressure by draining CSF are associated with reduced mortality in those with cryptococcal meningitis (with or without HIV). ^{[17] [47] [11]} But in those with suspicion of non-communicating hydrocephalus (which may present as focal neurologic symptoms or impaired mentation), a CT or MRI of the brain is required prior to lumbar puncture to rule out hydrocephalus, due to the risk of brain herniation with lumbar puncture. Non-communicating hydrocephalus is rare in those with HIV-associated cryptococcal meningitis. ^[17]

IRIS

Immune reconstitution inflammatory syndrome is possible in those with cryptococcal infection, especially those with concurrent HIV starting anti-retroviral therapy. With anti-retroviral therapy for the HIV, the CD4+ T-cell counts recover and the restored immune system mounts an exaggerated, hyperinflammatory response against cryptococcal infection in the body. ^[17]

IRIS has a 5% incidence in those with HIV and cryptococcosis starting anti-retroviral therapy. It usually occurs within 4 weeks of starting anti-retroviral therapy. ^[17] The risk of IRIS is increased in those with a high fungal burden, lower CD4+ T-cell count, and lower inflammatory marker levels. ^[17]

Epidemiology

Cryptococcosis is usually associated with immunosuppressed people, such as those with AIDs, corticosteroid use, diabetes, and organ transplant. ^[48] Cryptococcus comprizes two clinically relevant species, Cryptococcus neoformans and Cryptococcus gattii. ^[49] C. gattii was previously thought to only be found in tropical climates and in immunocompetent persons, but recent findings of C. gattii in regions such as Canada and Western regions of North America have challenged this initial presumption of the geographic patterns. ^[50]

Data from 2009 estimated that of the almost one million cases of cryptococcal meningitis that occurred worldwide annually, 700,000 occurred in sub-Saharan Africa and 600,000 per year died. ^[14] In 2014, amongst people who had a low CD4+ cell count, the annual incidence rate was estimated to be 278,000 cases. Of those, 223,100 resulted in cryptococcal meningitis. ^[51] About 73% of cryptococcal meningitis cases occurred in Sub-Saharan Africa. More than 180,000 fatalities are attributed to cryptococcal meningitis, 135,000 of which occur in sub-Saharan Africa. Case fatality of cryptococcal meningitis varies widely depending on what country the infection occurs. In low-income countries the case fatality from cryptococcal meningitis is 70%. This differs from middle income countries where the case fatality rate is 40%. In wealthy countries the case fatality is 20%. ^[51] 19% of all AIDS related deaths are due to cryptococcal disease. ^[52] Cryptococcal disease is the second leading cause of death in those with HIV/AIDS, second only to tuberculosis, which is responsible for 40% of deaths. ^[53] In sub-Saharan Africa approximately a third of HIV patients will develop cryptococcosis. ^[54]

In the United States

In the United States incidence of cryptococcosis is estimated to be about 0.4-1.3 cases per 100,000 population and 2-7 cases per 100,000 in people affected with AIDS with a case fatality ratio of about 12%. Since 1990 the incidence of AIDs associated cryptococcosis fell by 90% due to the proliferation of antiretroviral therapy. ^{[55] [56]} The estimated prevalence of cryptococcosis cases amongst HIV patients in the U.S. is 2.8%. ^[57] In immunocompetent patients cryptococcus typically presents itself as Cryptococcus gattii . ^[56] Despite its rarity cryptococcus has been more commonly seen, with upwards of 20% of cases in immunocompetent people. ^[58] Over 50% of cryptococcosis infections in North America are caused by C. gattii. Though C. gattii was originally thought to be restricted to subtropical and tropical regions it has become more prevalent worldwide. ^[59] C. gattii has been found in over 90 people in the United States, most of these cases originating in Washington or Oregon. ^[60]

In sub-Saharan Africa

Sub-Saharan Africa is the main hub for HIV/AIDS worldwide. HIV/AIDS accounts for about 0.5% of the world's population. ^[61] Remarkably, sub-Saharan Africa holds 71% of HIV/AIDs cases. ^[62] Cryptococcal meningitis is a primary contributor to mortality among individuals with HIV/AIDS in sub-Saharan Africa. ^[63] Approximately 160,000 cases of cryptococcal meningitis are reported in West Africa, resulting in 130,000 deaths in sub-Saharan Africa. ^[64] Uganda is reported to have the highest occurrence of cryptococcus meningitis. ^[54] Reflecting that, Ethiopia has the least occurrence. ^[54] Presently, treatment options involve either a 7 or 14-day regimen of amphotericin-B, coupled with oral antifungal tablets or oral fluconazole. It is important to note, amphotericin-B is not considered a treatment, as it showed not a significant reduction in the mortality rate. ^[65]

Other animals

Cryptococcosis is also seen in cats and occasionally dogs. It is the most common deep fungal disease in cats, usually leading to chronic infection of the nose and sinuses, and skin ulcers. Cats may develop a bump over the bridge of the nose from local tissue inflammation. It can be associated with FeLV infection in cats. Cryptococcosis is most common in dogs and cats but cattle, sheep, goats, horses, wild animals, and birds can also be infected. Soil, fowl manure, and pigeon droppings are among the sources of infection. ^{[66] [67]}

References

1. "Cryptococcosis". NORD (National Organization for Rare Disorders). Retrieved 5 June 2021.
2. "Cryptococcosis". Lexico UK English Dictionary. Oxford University Press. Archived from the original on 2021-05-07.
3. "Cryptococcosis". Merriam-Webster.com Dictionary . Merriam-Webster.
4. "ICD-11 — ICD-11 for Mortality and Morbidity Statistics". icd.who.int. Retrieved 5 June 2021.
5. "Symptoms of C. neoformans Infection". Fungal Diseases. Centers for Disease Control and Prevention. 14 January 2021. Retrieved 6 June 2021.
6. Johnstone, Ronald B. (2017). "25. Mycoses and Algal infections". Weedon's Skin Pathology Essentials (2nd ed.). Elsevier. p. 446. ISBN   978-0-7020-6830-0.
7. "C. neoformans Infection". Fungal Diseases. Centers for Disease Control and Prevention. 29 December 2020. Retrieved 5 June 2021.
8. "Where C. gattii Infection Comes From". Fungal Disease. Centers for Disease Control and Prevention. 29 January 2021. Retrieved 5 June 2021.
9. Maziarz, Eileen K.; Perfect, John R. (2016). "Cryptococcosis". Infectious Disease Clinics of North America. 30 (1): 179–206. doi:10.1016/j.idc.2015.10.006. PMC   5808417 . PMID   26897067.
10. "Treatment for C. neoformans Infection". Fungal Diseases. Centers for Disease Control and Prevention. 14 January 2021. Retrieved 6 June 2021.
11. Perfect JR, et al. (1 February 2010). "Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America". Clinical Infectious Diseases. 50 (3): 291–322. doi:10.1086/649858. PMID   20047480.
12. "Where C. neoformans Infection Comes From". Fungal Diseases. Centers for Disease Control and Prevention. 2 February 2021. Retrieved 5 June 2021.
13. Sabiiti, Wilber; May, Robin C. (November 2012). "Mechanisms of infection by the human fungal pathogen Cryptococcus neoformans". Future Microbiology. 7 (11): 1297–1313. doi:10.2217/fmb.12.102. PMID   23075448.
14. Vallabhaneni, Snigdha; Mody, Rajal K.; Walker, Tiffany; Chiller, Tom (2016). "1. The global burden of fungal disease". In Sobel, Jack; Ostrosky-Zeichner, Luis (eds.). Fungal Infections, An Issue of Infectious Disease Clinics of North America. Philadelphia: Elsevier. pp. 3–4. ISBN   978-0-323-41649-8.
15. Walter JE, Atchison RW (July 1966). "Epidemiological and immunological studies of Cryptococcus neoformans". J Bacteriol. 92 (1): 82–7. doi:10.1128/jb.92.1.82-87.1966. PMC   276199 . PMID   5328755.
16. Alanazi, Abdulaziz H.; Adil, Mir S.; Lin, Xiaorong; Chastain, Daniel B.; Henao-Martínez, Andrés F.; Franco-Paredes, Carlos; Somanath, Payaningal R. (July 2022). "Elevated Intracranial Pressure in Cryptococcal Meningoencephalitis: Examining Old, New, and Promising Drug Therapies". Pathogens. 11 (7): 783. doi: 10.3390/pathogens11070783 . PMC   9321092 . PMID   35890028.
17. Meya, David B.; Williamson, Peter R. (2 May 2024). "Cryptococcal Disease in Diverse Hosts". New England Journal of Medicine. 390 (17): 1597–1610. doi:10.1056/NEJMra2311057. PMID   38692293.
18. Setianingrum, Findra; Rautemaa-Richardson, Riina; Denning, David W (February 2019). "Pulmonary cryptococcosis: A review of pathobiology and clinical aspects". Medical Mycology. 57 (2): 133–150. doi: 10.1093/mmy/myy086 . PMID   30329097 . Retrieved 2022-08-18.
19. "Meningitis: cryptococcal: Overview". Medical Reference: Encyclopedia. University of Maryland Medical Center. September 2010. Archived from the original on 2013-05-23. Retrieved 2011-04-26.
20. Gushiken, Alexis C.; Saharia, Kapil K.; Baddley, John W. (June 2021). "Cryptococcosis". Infectious Disease Clinics. 35 (2): 493–514. doi:10.1016/j.idc.2021.03.012. PMID   34016288. S2CID   235074157.
21. Tucker JS, Guess TE, McClelland EE (2020). "The Role of Testosterone and Gibberellic Acid in the Melanization of Cryptococcus neoformans". Front Microbiol. 11: 1921. doi: 10.3389/fmicb.2020.01921 . PMC   7456850 . PMID   32922377.
22. Du L, Yang Y, Gu J, Chen J, Liao W, Zhu Y (August 2015). "Systemic Review of Published Reports on Primary Cutaneous Cryptococcosis in Immunocompetent Patients". Mycopathologia. 180 (1–2): 19–25. doi:10.1007/s11046-015-9880-7. PMID   25736173.
23. Murakawa GJ, Kerschmann R, Berger T (May 1996). "Cutaneous Cryptococcus infection and AIDS. Report of 12 cases and review of the literature". Arch Dermatol. 132 (5): 545–8. doi:10.1001/archderm.1996.03890290079010. PMID   8624151.
24. Choi KH, Park SJ, Min KH, Kim SR, Lee MH, Chung CR, Han HJ, Lee YC (May 2011). "Treatment of asymptomatic pulmonary cryptococcosis in immunocompetent hosts with oral fluconazole". Scand J Infect Dis. 43 (5): 380–5. doi:10.3109/00365548.2011.552521. PMID   21271944.
25. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE (April 2000). "Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America". Clin Infect Dis. 30 (4): 710–8. doi:10.1086/313757. PMID   10770733.
26. Brizendine KD, Baddley JW, Pappas PG (December 2011). "Pulmonary cryptococcosis". Semin Respir Crit Care Med. 32 (6): 727–34. doi:10.1055/s-0031-1295720. PMID   22167400.
27. Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM (2009-02-20). "Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS". AIDS. 23 (4): 525–30. doi: 10.1097/QAD.0b013e328322ffac . PMID   19182676. S2CID   5735550.
28. D’Souza, C. A.; et al. (2011-02-08). "Genome Variation in Cryptococcus gattii, an Emerging Pathogen of Immunocompetent Hosts". mBio. 2 (1). American Society for Microbiology: e00342-10. doi:10.1128/mBio.00342-10. PMC   3037005 . PMID   21304167.
29. Pasquier E, Kunda J, De Beaudrap P, Loyse A, Temfack E, Molloy SF, Harrison TS, Lortholary O (March 2018). "Long-term Mortality and Disability in Cryptococcal Meningitis: A Systematic Literature Review". Clin Infect Dis. 66 (7): 1122–32. doi:10.1093/cid/cix870. PMID   29028957.
30. Anjum S, Williamson PR (September 2019). "Clinical Aspects of Immune Damage in Cryptococcosis". Curr Fungal Infect Rep. 13 (3): 99–108. doi:10.1007/s12281-019-00345-7. PMC   7580832 . PMID   33101578.
31. Neal LM, Xing E, Xu J, Kolbe JL, Osterholzer JJ, Segal BM, Williamson PR, Olszewski MA (November 2017). "CD4+ T Cells Orchestrate Lethal Immune Pathology despite Fungal Clearance during Cryptococcus neoformans Meningoencephalitis". mBio. 8 (6): e01415–17. doi:10.1128/mBio.01415-17. PMC   5698549 . PMID   29162707.
32. Rhein, J; Boulware DR (2012). "Prognosis and management of cryptococcal meningitis in patients with HIV infection". Neurobehavioral HIV Medicine. 4: 45. doi: 10.2147/NBHIV.S24748 .
33. Zerpa, R; Huicho, L; Guillén, A (September 1996). "Modified India ink preparation for Cryptococcus neoformans in cerebrospinal fluid specimens". Journal of Clinical Microbiology. 34 (9): 2290–1. doi:10.1128/JCM.34.9.2290-2291.1996. PMC   229234 . PMID   8862601.
34. Boulware, DR; Rolfes, MA; Rajasingham, R; von Hohenberg, M; Qin, Z; Taseera, K; Schutz, C; Kwizera, R; Butler, EK; Meintjes, G; Muzoora, C; Bischof, JC; Meya, DB (Jan 2014). "Multisite validation of cryptococcal antigen lateral flow assay and quantification by laser thermal contrast". Emerging Infectious Diseases. 20 (1): 45–53. doi:10.3201/eid2001.130906. PMC   3884728 . PMID   24378231.
35. "FIGURE 1. Prevalence of asymptomatic antigenemia with corresponding cost per life saved based on LFA cost of $2.50 per test".
36. Meya DB, Manabe YC, Castelnuovo B, Cook BA, Elbireer AM, Kambugu A, Kamya MR, Bohjanen PR, Boulware DR (August 2010). "Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings". Clin. Infect. Dis. 51 (4): 448–55. doi:10.1086/655143. PMC   2946373 . PMID   20597693.
37. Rajasingham, R; Meya, DB; Boulware, DR (Apr 15, 2012). "Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care". Journal of Acquired Immune Deficiency Syndromes. 59 (5): e85–91. doi:10.1097/QAI.0b013e31824c837e. PMC   3311156 . PMID   22410867.
38. World Health Organization. "Rapid advice: Diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents, and children". Archived from the original on February 21, 2014. Retrieved 1 August 2012.
39. Jarvis, JN; Harrison, TS; Govender, N; Lawn, SD; Longley, N; Bicanic, T; Maartens, G; Venter, F; Bekker, LG; Wood, R; Meintjes, G (2011). "Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts—time to implement in South Africa?" (PDF). South African Medical Journal. 101 (4): 232–4. doi: 10.7196/samj.4752 (inactive 2024-11-10). PMID   21786721.
40. Rajasingham, R; Boulware, DR (Dec 2012). "Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 <100 cells/mcL". Clinical Infectious Diseases. 55 (12): 1742–4. doi:10.1093/cid/cis725. PMC   3501329 . PMID   22918997.
41. McKenney J, Smith RM, Chiller TM, Detels R, French A, Margolick J, Klausner JD (July 2014). "Prevalence and correlates of cryptococcal antigen positivity among AIDS patients—United States, 1986–2012". MMWR Morb. Mortal. Wkly. Rep. 63 (27): 585–7. PMC   4584711 . PMID   25006824.
42. Awotiwon, Ajibola A; Johnson, Samuel; Rutherford, George W; Meintjes, Graeme; Eshun-Wilson, Ingrid (2018-08-29). Cochrane Infectious Diseases Group (ed.). "Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people". Cochrane Database of Systematic Reviews. 2018 (8): CD004773. doi:10.1002/14651858.CD004773.pub3. PMC   6513489 . PMID   30156270.
43. "Practice Guidelines for the Management of Cryptococcal Disease". Infectious Disease Society of America. 2010. Archived from the original on 2018-07-25. Retrieved 2013-09-14.
44. Rajasingham, Radha; Rolfes, M.A.; Birkenkamp, K.E.; Meya, D.B.; Boulware, D.R. (2012). Farrar, Jeremy (ed.). "Cryptococcal Meningitis Treatment Strategies in Resource-Limited Settings: A Cost-Effectiveness Analysis". PLOS Medicine. 9 (9): e1001316. doi: 10.1371/journal.pmed.1001316 . PMC   3463510 . PMID   23055838.
45. Boulware, DR; Meya, DB; Muzoora, Conrad; Rolfes, MA; Huppler Hullsiek, K; Musubire, Abdu; Taseera, Kabanda; Nabeta, HW; Schutz, C; Williams, DA A.; Rajasingham, R; Rhein, J; Thienemann, F; Lo, MW; Nielsen, K; Bergemann, T L.; Kambugu, A; Manabe, YC; Janoff, EN; Bohjanen, PR; Meintjes, G (26 June 2014). "Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis". New England Journal of Medicine. 370 (26): 2487–98. doi:10.1056/NEJMoa1312884. PMC   4127879 . PMID   24963568.
46. Eshun-Wilson, Ingrid; Okwen, Mbah P.; Richardson, Marty; Bicanic, Tihana (24 July 2018). "Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis". The Cochrane Database of Systematic Reviews. 2018 (7): CD009012. doi:10.1002/14651858.CD009012.pub3. PMC   6513637 . PMID   30039850.
47. Rolfes, et al. (1 December 2014). "The Effect of Therapeutic Lumbar Punctures on Acute Mortality From Cryptococcal Meningitis". Clinical Infectious Diseases. 59 (11): 1607–1614. doi:10.1093/cid/ciu596.
48. Mada, Pradeep Kumar; Jamil, Radia T.; Alam, Mohammed U. (2023), "Cryptococcus", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID   28613714 , retrieved 2023-11-15
49. Choi YH, Ngamskulrungroj P, Varma A, Sionov E, Hwang SM, Carriconde F, Meyer W, Litvintseva AP, Lee WG, Shin JH, Kim EC, Lee KW, Choi TY, Lee YS, Kwon-Chung KJ (September 2010). "Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV-associated cryptococcosis in the Republic of Korea". FEMS Yeast Res. 10 (6): 769–78. doi:10.1111/j.1567-1364.2010.00648.x. PMC   2920376 . PMID   20561059.
50. Harris, Julie; Lockhart, Shawn; Chiller, Tom (February 2012). "Cryptococcus gattii: where do we go from here?". Medical Mycology. 50 (2): 113–129. doi:10.3109/13693786.2011.607854. PMID   21939343. S2CID   21577621.
51. Rajasingham, Radha; Smith, Rachel M; Park, Benjamin J; Jarvis, Joseph N; Govender, Nelesh P; Chiller, Tom M; Denning, David W; Loyse, Angela; Boulware, David R (August 2017). "Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis". The Lancet Infectious Diseases. 17 (8): 873–881. doi:10.1016/S1473-3099(17)30243-8. PMC   5818156 . PMID   28483415.
52. Rajasingham, Radha; Govender, Nelesh P; Jordan, Alexander; Loyse, Angela; Shroufi, Amir; Denning, David W; Meya, David B; Chiller, Tom M; Boulware, David R (December 2022). "The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis". The Lancet Infectious Diseases. 22 (12): 1748–1755. doi:10.1016/S1473-3099(22)00499-6. PMID   36049486.
53. Meintjes, Graeme; Maartens, Gary (25 July 2024). "HIV-Associated Tuberculosis". New England Journal of Medicine. 391 (4): 343–355. doi:10.1056/NEJMra2308181.
54. Alemayehu, Tsegaye; Ayalew, Sosina; Buzayehu, Temesgen; Daka, Deresse (2020-04-20). "Magnitude of Cryptococcosis among HIV patients in sub-Saharan Africa countries: a systematic review and meta-analysis". African Health Sciences. 20 (1): 114–121. doi:10.4314/ahs.v20i1.16. PMC   7750036 . PMID   33402899.
55. "C. neoformans Infection Statistics". Fungal Diseases. Centers for Disease Control and Prevention. 2022-11-02. Retrieved 2023-11-15.
56. Mada, Pradeep Kumar; Jamil, Radia T.; Alam, Mohammed U. (2023), "Cryptococcus", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID   28613714, NBK431060, retrieved 2023-11-15
57. Alemayehu, Tsegaye; Ayalew, Sosina; Buzayehu, Temesgen; Daka, Deresse (2020-04-20). "Magnitude of Cryptococcosis among HIV patients in sub-Saharan Africa countries: a systematic review and meta-analysis". African Health Sciences. 20 (1): 114–121. doi:10.4314/ahs.v20i1.16. PMC   7750036 . PMID   33402899.
58. Stack M, Hiles J, Valinetz E, Gupta SK, Butt S, Schneider JG (August 2023). "Cryptococcal Meningitis in Young, Immunocompetent Patients: A Single-Center Retrospective Case Series and Review of the Literature". Open Forum Infect Dis. 10 (8): ofad420. doi:10.1093/ofid/ofad420. PMC   10456216 . PMID   37636518.
59. Howard-Jones, Annaleise R.; Sparks, Rebecca; Pham, David; Halliday, Catriona; Beardsley, Justin; Chen, Sharon C.-A. (November 2022). "Pulmonary Cryptococcosis". Journal of Fungi. 8 (11): 1156. doi: 10.3390/jof8111156 . PMC   9696922 . PMID   36354923.
60. Harris, Julie; Lockhart, Shawn; Chiller, Tom (February 2012). "Cryptococcus gattii: where do we go from here?". Medical Mycology. 50 (2): 113–129. doi:10.3109/13693786.2011.607854. PMID   21939343. S2CID   21577621.
61. "HIV and AIDS Epidemic Global Statistics". HIV.gov. Retrieved 2023-12-12.
62. Kharsany, Ayesha B.M.; Karim, Quarraisha A. (2016-04-08). "HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities". The Open AIDS Journal. 10: 34–48. doi:10.2174/1874613601610010034. PMC   4893541 . PMID   27347270.
63. "C. neoformans Infection Statistics". Fungal Diseases. Centers for Disease Control and Prevention. 2022-11-02. Retrieved 2023-11-26.
64. Akaihe, Chidinma Lynda; Nweze, Emeka Innocent (January 2021). "Epidemiology of Cryptococcus and cryptococcosis in Western Africa". Mycoses. 64 (1): 4–17. doi:10.1111/myc.13188. PMID   32969547. S2CID   221884476.
65. Patel, Raju K K; Leeme, Tshepo; Azzo, Caitlin; Tlhako, Nametso; Tsholo, Katlego; Tawanana, Ephraim O; Molefi, Mooketsi; Mosepele, Mosepele; Lawrence, David S; Mokomane, Margaret; Tenforde, Mark W; Jarvis, Joseph N (2018-11-01). "High Mortality in HIV-Associated Cryptococcal Meningitis Patients Treated With Amphotericin B–Based Therapy Under Routine Care Conditions in Africa". Open Forum Infectious Diseases. 5 (11): ofy267. doi:10.1093/ofid/ofy267. PMC   6251350 . PMID   30488038.
66. "Deep Fungal Infections". Archived from the original on 2010-04-13.
67. Akira Takeuchi, D. V. M. (July 2014). "Feline Cryptococcosis – WSAVA 2003 Congress – VIN". Vin.com.

Further reading

• Perfect JR, et al. (2010). "Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america". Clinical Infectious Diseases . 50 (3): 291–322. doi:10.1086/649858. PMC   5826644 . PMID   20047480.
• Gullo FP, et al. (2013). "Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment". European Journal of Clinical Microbiology & Infectious Diseases. 32 (11): 1377–1391. doi:10.1007/s10096-013-1915-8. PMID   24141976. S2CID   11317427.
• Perfect JR, et al. (2005). "Cryptococcus neoformans: a sugar-coated killer with designer genes". FEMS Immunology and Medical Microbiology. 45 (11): 395–404. doi: 10.1016/j.femsim.2005.06.005 . PMID   16055314. (Review)

External links

• Medscape entry on cryptococcosis